BioSpace News Archive

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the presentation and publication of two clinical cases demonstrating proof-of-concept for BLU-667 in combination with osimertinib (Tagrisso®) in treatment-resistant, EGFR-mutant non-small cell lung cancer

Audentes Therapeutics, Inc. today announced that it will participate in the following investor conferences in October:

Award extends 30-year legacy providing science and engineering expertise

The Chan Zuckerberg Biohub (CZ Biohub), a nonprofit medical research organization, today announced that it is awarding $13.7 million over three years to support cutting-edge biomedical research from seven teams of scientists, physicians, and engineers, with each team including faculty members from the University of California, San Francisco (UCSF), the University of California, Berkeley (UC Berkeley), and Stanford University.

NantEnergy today announced a breakthrough in its six-year mission to develop the world’s first scalable air breathing zinc rechargeable battery system at a manufacturing cost below $100 kWh and to operate this intelligent digitally controlled system on a global scale.

Humanetics Corporation (Humanetics) has been invited to present data at the 64th Annual Meeting of the Radiation Research Society (RRS) being held September 23rd through the 26th in Chicago, IL. Adam Harvey, Ph.D., of Humanetics will present data related to Humanetics’ new drug candidate, BIO 300.

Care1st Health Plan Arizona, a WellCare Health Plans, Inc. (NYSE: WCG) company, is hosting a two-day hiring event on Oct. 8 and 9 to help fill more than 130 open positions in Arizona.

NuVasive, Inc.(NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it enrolled its first patients in a prospective, multicenter study evaluating advanced spinal implants used in XLIF® procedures and their effect on long-term patient outcomes.

DCN Dx and E25Bio have announced a partnership for the design, development and manufacture of an innovative new infectious disease testing technology.

Novus Therapeutics Inc. announced that Gregory J. Flesher, Chief Executive Officer of Novus, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York City on Tuesday, October 2, 2018 at 9:30 AM Eastern Time.